Organisation paid for research Program year 2024 Source: CMS Open Payments

CNR LLC

Neither a doctor nor a teaching hospital

Research payments

$466,793

51 payments

Through program year 2024, CNR LLC is reported as receiving $466,793 in research payments, across 51 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $24,742 2
2022 Research $170,593 13
2021 Research $263,796 34
2020 Research $7,663 2

Breakdown

Who paid Research payments · program years 2020–2024
  1. Biohaven Pharmaceuticals, Inc. $271,458 36 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $170,593 13 payments
  3. BioXcel Therapeutics, Inc. $24,742 2 payments
Studies the money was for Research payments · program years 2020–2024
  1. Phase 1: Open-Label 8-Week Safety Study of Oral Zavegepant (BHV-3500) in Normal Healthy Subjects $333,476 23 payments
  2. A Phase III Long-Term Randomized Doubleblind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia $77,547 14 payments
  3. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $22,466 8 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of Bxcl501 Over A 12 Week Period in Subjects With Agitation Associated With Dementia $20,242 1 payment
  5. A Phase III, Long-Term, Randomized, Doubleblind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia $6,788 1 payment
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of Bxcl501 Over A 12 Week Treatment Period in Subjects With Agitation Associated With Dementia Who Require at Least Moderate to Full Assistance With Activities of Daily Living $4,500 1 payment
  7. A Phase IIb/III Randomized Double-blind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia $900 2 payments
  8. A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia $875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record